# NIH grant: Lung Protective Immunity Elicited by Parental Yersinia-Vesicle Vaccine Against Pneumonic Plague (1R01AI201175-01) — retained record

> Retained us-gov-api record from us-gov-api:nih-reporter.

Canonical: https://highsignal.app/data/records/eeda8a0b4b2f932f

[← sources](https://highsignal.app/data)


source: [us-gov-api](https://highsignal.app/data/us-gov-api) (us-gov-api:nih-reporter)  published 2026-07-23 00:00 ingested 2026-07-27 09:46

[original source ↗](https://reporter.nih.gov/project-details/1R01AI201175-01)

## retained text



```
NIH grant 1R01AI201175-01: Lung Protective Immunity Elicited by Parental Yersinia-Vesicle Vaccine Against Pneumonic Plague
Institute: {'code': 'AI', 'abbreviation': 'NIAID', 'name': 'National Institute of Allergy and Infectious Diseases', 'admin_org_id': '12500003', 'admin_funding_url': ''}. PI: Wei  Sun. Award: $633136.
Start: 2026-07-23T00:00:00.
SUMMARY
Yersinia pestis is a causative agent of plague. Among different plague forms, the primary pneumonic
plague is the deadliest form of human disease.In addition, the appearanceof multiple drug-resistant Y. pestis
may cause potential failure of antibiotic treatment. Thus, developing an effective plague vaccine for emergency
use is imperative. Our
of
established studies have indicated that
 plague vaccine, Yersinia OMVs (O
 intramuscular (IM) immunization
MV46-LcrV), instead of LcrV or F-V subunit antigen, induces robust
with a new type
adaptive responses in both systemic and lung mucosal compartments and significant elevation of alveolar
macrophage (AM) numbers, which provide excellent short- and long-term protection against pulmonary Y.
pestis challenge. However, how
pneumonic
propose
infection. Moreover, a better understanding of lung immune mechanisms after immunization will undoubtedly
 IM O immunization distantly remodels lung immunity against
 plague, particularly about lung T cells, AMs, and their interrelation, remains elusive. Here, we
 to decipher these cells and their interrelation in the lung after immunization and upon pulmonary
MV46-LcrV
aid the development of effective pneumonic plague vaccines.
```



document fetched 2026-08-02 08:24